Month: September 2022

Savosolar Plc Company Announcement             20 September 2022 at 8.30 a.m. (CEST)Savosolar Plc – Managers’ Transaction, Ari Virtanen, September 2022   Person subject to the notification requirementName: Virtanen Ari Tapani  Position: Member of the Board/Deputy member     Initial Notification  Reference number: 19717/4/4     IssuerName: Savosolar OyjLEI: 743700J1YZ8IEJAPDL21     Transaction detailsTransaction date: 2022-09-19Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Nature of the transaction: Subscription Instrument: ShareISIN: FI4000425848 Volume: 6450Unit price: 0.05600 Euro Aggregated transactionsVolume: 6450Volume weighted average price: 0.05600 EuroSAVOSOLAR PLC For more information: Savosolar Plc Managing Director Jari Varjotie Phone: +358 400...

New contract amendment with Public Health Agency of Canada for the supply of IMVAMUNE valued at USD 234 million, with additional options spanning 10 years valued at USD 180 million Under the new contract amendment, the majority of the confirmed order will be delivered in 2023 Furthermore, a multi-year contract valued at up to USD 20 million has been signed with the Canadian Department of National Defence, until 2031COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today a revised contract with the Public Health Agency of Canada (PHAC) to supply doses of IMVAMUNE® smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options. This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million. Furthermore, a new multi-year...

Company announcement no. 32 In company announcement no. 9 2022, Spar Nord announced a share buyback programme of up to DKK 225 million. The share buyback was initiated on 15 June 2022. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 37, the following transactions were made under the share buyback programme.  Number of shares Average purchase price Transaction value (DKK)Accumulated from last announcement 1,252,000     101,060,61212 September 2022  19,000  90.24  1,714,56013 September 2022  17,000  92.02  1,564,34014 September 2022  16,000  91.19  1,459,04015 September 2022  16,000  92.00  1,472,00016 September 2022  15,000...

SAMPO PLC                 STOCK EXCHANGE RELEASE         20/09/2022 at 08:30 am Sampo plc’s share buybacks 19/09/2022 On 19/09/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  12,447 45.56 AQEU  30,214 45.58 CEUX  6,880 45.60 TQEX  74,398 45.54 XHELTOTAL 123,939 45.56  *rounded to two decimals                 On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based...

Geneva, Switzerland, September 20, 2022 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 – 22, 2022 and September 23, 2022, respectively. In his presentations, Mr. Dyer will provide a corporate update and discuss recent developments at Addex. A video of each presentation will be available for viewing on-demand by registered participants. Mr. Dyer will also participate in a neurodegenerative diseases roundtable discussion with other panelists at the Sachs Associates Conference, scheduled on September 22, 2022. Mr....

Hepsor N57 OÜ, a subsidiary of Hepsor AS, acquired a property at Nõmme tee 57, Tallinn on 19 August 2022. The construction of the development project located in peaceful and green Kristiine administrative district will begin already in the fourth quarter of 2022. The development project has 26 apartments of different sizes, from compact one-room apartments to spacious four-room apartments with large terraces. Henri Laks, member of the Management Board of Hepsor AS, said: „Over the last year we have added 9 new development projects including 4 in Estonia and 5 in Latvia. Total addition amounts to approximately 430 apartments (incl ca 250 in Estonia and ca 180 in Latvia), which is about 26% of Group’s residential development projects, and approximately 27,700 m2 of commercial property mostly in Latvia. The construction of acquired development...

NorthStar is further expanding commercial-scale domestic radioisotope production capabilities using IBA’s environmentally preferable Rhodotron® accelerator technology Louvain-La-Neuve, Belgium, and BELOIT, Wisconsin, USA September 20, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a new agreement under which NorthStar will purchase two additional Rhodotron® TT300 HE electron beam accelerators, and the associated beamlines, from IBA for the production of molybdenum-99 (Mo-99). The purchase marks a total of five Rhodotron® accelerators that NorthStar has purchased from IBA to...

GOSSELIES, Belgium and MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2022 (GLOBE NEWSWIRE) — Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including the existing facility and all related personnel (the “Manufacturing Business Unit”). Under the terms of an asset purchase agreement between Celyad Oncology and Cellistic, Cellistic agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for a total consideration of...

Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net sales Second oncology transaction as part of strategic refocusing on anti-infectives Full-year 2022 revenue guidance increased, resulting in improved expected operating result and operating cash flowAd hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, September 20, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement and a sub-license agreement with SillaJen, Inc. for Basilea’s novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, that drives...